Abstract Search

ey0015.9-12 | Biologic agents in chronic inflammatory diseases: lights and shadows | ESPEYB15

9.12 Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn’s Disease

TD Walters , WA Faubion , AM Griffiths , RN Baldassano , J Escher , FM Ruemmele , JS Hyams , A Lazar , S Eichner , B Huang , Y Li , RB Thakkar

To read the full abstract: Inflamm Bowel Dis. 2017;23:967-975Approximately one-third of children and adolescents with Crohn disease (CD) suffer from growth failure and delayed puberty, leading in some to psychological and social dysfunction, especially in boys. Pubertal delay in CD may also impact the normal growth spurt and lead to short adult height. The aim of therapy in children with C...

0 shares

ey0015.9-11 | Biologic agents in chronic inflammatory diseases: lights and shadows | ESPEYB15

9.11 Perianal pediatric Crohn disease is associated with a distinct phenotype and greater inflammatory burden

A Assa , M Amitai , ML Greer , DA Castro , RC Kuint , M Martínez-León , I Herman-Sucharska , E Coppenrath , S Anupindi , A Towbin , D Moote , O Konen , LT Pratt , A Griffiths , D Turner , ImageKids Study Group

To read the full abstract: J Pediatr Gastroenterol Nutr. 2017;65:293-298Growth deceleration and impaired pubertal growth spurt are common concerns in patients with early onset inflammatory bowel disease (IBD) (1-2). Previous studies confirmed the efficacy and safety of infliximab, an anti-tumor necrosis factor alpha (TNF-α) antibody, in achieving clinical remission in luminal Crohn&#8...

0 shares

ESPE Yearbook of Paediatric Endocrinology

9.12 Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn’s Disease

9.11 Perianal pediatric Crohn disease is associated with a distinct phenotype and greater inflammatory burden

BiosciAbstracts